Precipio, Inc. (NASDAQ: PRPO) Stock Competitors & Peer Comparison
See PRPO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PRPO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRPO | $23.45 | -2.29% | 41.8M | -36.08 | -$0.65 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.70% |
| TMO | $656.58 | -2.98% | 242.8B | 28.35 | $23.16 | +0.28% |
| DHR | $215.61 | -2.53% | 151.5B | 27.01 | $7.98 | +0.70% |
| NTRA | $400.65 | -5.87% | 57.4B | -303.52 | -$1.32 | N/A |
| A | $169.33 | -1.14% | 47.8B | 29.15 | $5.81 | +0.60% |
| WAT | $436.43 | -0.84% | 42.9B | 31.90 | $13.68 | N/A |
| IQV | $259.98 | -2.30% | 42.8B | 21.45 | $12.13 | N/A |
| ILMN | $273.54 | -6.86% | 41.4B | 54.38 | $5.03 | N/A |
| IDXX | $515.41 | -2.21% | 40.7B | 36.25 | $14.22 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
PRPO vs DHR-PB Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, PRPO's ROE is -0.08%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, PRPO is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
PRPO vs TMO Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, TMO has a market cap of 242.8B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while TMO trades at $656.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas TMO's P/E ratio is 28.35. In terms of profitability, PRPO's ROE is -0.08%, compared to TMO's ROE of +0.13%. Regarding short-term risk, PRPO is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
PRPO vs DHR Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, DHR has a market cap of 151.5B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while DHR trades at $215.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas DHR's P/E ratio is 27.01. In terms of profitability, PRPO's ROE is -0.08%, compared to DHR's ROE of +0.08%. Regarding short-term risk, PRPO is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
PRPO vs NTRA Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, NTRA has a market cap of 57.4B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while NTRA trades at $400.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas NTRA's P/E ratio is -303.52. In terms of profitability, PRPO's ROE is -0.08%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, PRPO is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
PRPO vs A Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, A has a market cap of 47.8B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while A trades at $169.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas A's P/E ratio is 29.15. In terms of profitability, PRPO's ROE is -0.08%, compared to A's ROE of +0.20%. Regarding short-term risk, PRPO is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check A's competition here
Waters Corporation (NYSE: WAT)
PRPO vs WAT Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, WAT has a market cap of 42.9B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while WAT trades at $436.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas WAT's P/E ratio is 31.90. In terms of profitability, PRPO's ROE is -0.08%, compared to WAT's ROE of +0.02%. Regarding short-term risk, PRPO is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check WAT's competition here
IQVIA Holdings Inc. (NYSE: IQV)
PRPO vs IQV Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, IQV has a market cap of 42.8B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while IQV trades at $259.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas IQV's P/E ratio is 21.45. In terms of profitability, PRPO's ROE is -0.08%, compared to IQV's ROE of +0.22%. Regarding short-term risk, PRPO is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check IQV's competition here
Illumina, Inc. (NASDAQ: ILMN)
PRPO vs ILMN Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, ILMN has a market cap of 41.4B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while ILMN trades at $273.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas ILMN's P/E ratio is 54.38. In terms of profitability, PRPO's ROE is -0.08%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, PRPO is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check ILMN's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
PRPO vs IDXX Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, IDXX has a market cap of 40.7B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while IDXX trades at $515.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas IDXX's P/E ratio is 36.25. In terms of profitability, PRPO's ROE is -0.08%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, PRPO is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check IDXX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
PRPO vs MTD Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, MTD has a market cap of 31B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while MTD trades at $1,533.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas MTD's P/E ratio is 35.21. In terms of profitability, PRPO's ROE is -0.08%, compared to MTD's ROE of -12.00%. Regarding short-term risk, PRPO is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
PRPO vs LH Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, LH has a market cap of 25.6B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while LH trades at $311.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas LH's P/E ratio is 18.50. In terms of profitability, PRPO's ROE is -0.08%, compared to LH's ROE of +0.12%. Regarding short-term risk, PRPO is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
PRPO vs DGX Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, DGX has a market cap of 25.2B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while DGX trades at $228.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas DGX's P/E ratio is 22.53. In terms of profitability, PRPO's ROE is -0.08%, compared to DGX's ROE of +0.14%. Regarding short-term risk, PRPO is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
PRPO vs GH Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, GH has a market cap of 22.9B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while GH trades at $170.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas GH's P/E ratio is -48.91. In terms of profitability, PRPO's ROE is -0.08%, compared to GH's ROE of +2.11%. Regarding short-term risk, PRPO is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
PRPO vs EXAS Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas EXAS's P/E ratio is -95.37. In terms of profitability, PRPO's ROE is -0.08%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, PRPO is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check EXAS's competition here
Revvity, Inc. (NYSE: RVTY)
PRPO vs RVTY Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, RVTY has a market cap of 17.1B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while RVTY trades at $153.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas RVTY's P/E ratio is 28.66. In terms of profitability, PRPO's ROE is -0.08%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, PRPO is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
PRPO vs ILMNV Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas ILMNV's P/E ratio is N/A. In terms of profitability, PRPO's ROE is -0.08%, compared to ILMNV's ROE of N/A. Regarding short-term risk, PRPO is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
PRPO vs MEDP Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, MEDP has a market cap of 16.8B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while MEDP trades at $602.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas MEDP's P/E ratio is 35.34. In terms of profitability, PRPO's ROE is -0.08%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, PRPO is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check MEDP's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
PRPO vs CRL Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, CRL has a market cap of 14.7B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while CRL trades at $304.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas CRL's P/E ratio is 30.81. In terms of profitability, PRPO's ROE is -0.08%, compared to CRL's ROE of -0.08%. Regarding short-term risk, PRPO is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check CRL's competition here
PerkinElmer, Inc. (NYSE: PKI)
PRPO vs PKI Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas PKI's P/E ratio is 41.45. In terms of profitability, PRPO's ROE is -0.08%, compared to PKI's ROE of +0.03%. Regarding short-term risk, PRPO is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
PRPO vs ICLR Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, ICLR has a market cap of 12.4B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while ICLR trades at $161.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas ICLR's P/E ratio is 13.19. In terms of profitability, PRPO's ROE is -0.08%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, PRPO is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
PRPO vs QGEN Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, QGEN has a market cap of 9.4B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while QGEN trades at $45.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas QGEN's P/E ratio is 18.87. In terms of profitability, PRPO's ROE is -0.08%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, PRPO is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
PRPO vs GRAL Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, GRAL has a market cap of 5.9B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while GRAL trades at $137.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas GRAL's P/E ratio is -14.08. In terms of profitability, PRPO's ROE is -0.08%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, PRPO is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
PRPO vs RDNT Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while RDNT trades at $70.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas RDNT's P/E ratio is 152.78. In terms of profitability, PRPO's ROE is -0.08%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, PRPO is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
PRPO vs SHC Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while SHC trades at $18.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas SHC's P/E ratio is 19.01. In terms of profitability, PRPO's ROE is -0.08%, compared to SHC's ROE of +0.27%. Regarding short-term risk, PRPO is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
PRPO vs BLLN Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, BLLN has a market cap of 4.6B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while BLLN trades at $99.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas BLLN's P/E ratio is 142.72. In terms of profitability, PRPO's ROE is -0.08%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, PRPO is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
PRPO vs SYNH Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas SYNH's P/E ratio is 61.40. In terms of profitability, PRPO's ROE is -0.08%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, PRPO is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
PRPO vs VCYT Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while VCYT trades at $44.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas VCYT's P/E ratio is 22.33. In terms of profitability, PRPO's ROE is -0.08%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, PRPO is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
PRPO vs CDNA Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while CDNA trades at $63.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas CDNA's P/E ratio is 75.94. In terms of profitability, PRPO's ROE is -0.08%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, PRPO is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
PRPO vs OLK Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas OLK's P/E ratio is -96.59. In terms of profitability, PRPO's ROE is -0.08%, compared to OLK's ROE of -0.07%. Regarding short-term risk, PRPO is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
PRPO vs WGS Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, WGS has a market cap of 2.1B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while WGS trades at $71.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas WGS's P/E ratio is 198.67. In terms of profitability, PRPO's ROE is -0.08%, compared to WGS's ROE of -0.39%. Regarding short-term risk, PRPO is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
PRPO vs PSNL Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while PSNL trades at $16.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas PSNL's P/E ratio is -14.71. In terms of profitability, PRPO's ROE is -0.08%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, PRPO is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
PRPO vs OPK Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while OPK trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas OPK's P/E ratio is -16.22. In terms of profitability, PRPO's ROE is -0.08%, compared to OPK's ROE of -0.06%. Regarding short-term risk, PRPO is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
PRPO vs CSTL Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while CSTL trades at $33.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas CSTL's P/E ratio is -50.55. In terms of profitability, PRPO's ROE is -0.08%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, PRPO is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
PRPO vs FLGT Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, FLGT has a market cap of 584.5M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while FLGT trades at $20.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas FLGT's P/E ratio is 2058.00. In terms of profitability, PRPO's ROE is -0.08%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, PRPO is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
PRPO vs GRALV Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas GRALV's P/E ratio is N/A. In terms of profitability, PRPO's ROE is -0.08%, compared to GRALV's ROE of N/A. Regarding short-term risk, PRPO is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
PRPO vs NEO Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, NEO has a market cap of 424.1M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while NEO trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas NEO's P/E ratio is 126.96. In terms of profitability, PRPO's ROE is -0.08%, compared to NEO's ROE of -0.06%. Regarding short-term risk, PRPO is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
PRPO vs MYGN Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, MYGN has a market cap of 404.2M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while MYGN trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas MYGN's P/E ratio is -32.92. In terms of profitability, PRPO's ROE is -0.08%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, PRPO is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
PRPO vs CO Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas CO's P/E ratio is 5.06. In terms of profitability, PRPO's ROE is -0.08%, compared to CO's ROE of +0.11%. Regarding short-term risk, PRPO is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
PRPO vs FLDM Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas FLDM's P/E ratio is -4.74. In terms of profitability, PRPO's ROE is -0.08%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, PRPO is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
PRPO vs BDSX Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, BDSX has a market cap of 227.6M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while BDSX trades at $27.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas BDSX's P/E ratio is -8.82. In terms of profitability, PRPO's ROE is -0.08%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, PRPO is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
PRPO vs XGN Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, XGN has a market cap of 197.9M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while XGN trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas XGN's P/E ratio is -10.11. In terms of profitability, PRPO's ROE is -0.08%, compared to XGN's ROE of -1.22%. Regarding short-term risk, PRPO is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
PRPO vs FRNM Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, FRNM has a market cap of 133.5M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while FRNM trades at $16.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas FRNM's P/E ratio is N/A. In terms of profitability, PRPO's ROE is -0.08%, compared to FRNM's ROE of N/A. Regarding short-term risk, PRPO is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
PRPO vs GTH Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas GTH's P/E ratio is -1.11. In terms of profitability, PRPO's ROE is -0.08%, compared to GTH's ROE of -1.01%. Regarding short-term risk, PRPO is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
PRPO vs GENE Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas GENE's P/E ratio is -38.25. In terms of profitability, PRPO's ROE is -0.08%, compared to GENE's ROE of -1.85%. Regarding short-term risk, PRPO is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
PRPO vs IMDX Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, IMDX has a market cap of 109.1M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while IMDX trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas IMDX's P/E ratio is -2.27. In terms of profitability, PRPO's ROE is -0.08%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, PRPO is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
PRPO vs SERA Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, SERA has a market cap of 78.3M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while SERA trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas SERA's P/E ratio is -3.15. In terms of profitability, PRPO's ROE is -0.08%, compared to SERA's ROE of -0.47%. Regarding short-term risk, PRPO is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check SERA's competition here
MDxHealth S.A. (NASDAQ: MDXH)
PRPO vs MDXH Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, MDXH has a market cap of 30.8M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while MDXH trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas MDXH's P/E ratio is -0.82. In terms of profitability, PRPO's ROE is -0.08%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, PRPO is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
PRPO vs QUCY Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, QUCY has a market cap of 29.4M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while QUCY trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas QUCY's P/E ratio is -0.06. In terms of profitability, PRPO's ROE is -0.08%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, PRPO is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
PRPO vs AKU Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas AKU's P/E ratio is -0.13. In terms of profitability, PRPO's ROE is -0.08%, compared to AKU's ROE of -5.32%. Regarding short-term risk, PRPO is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
PRPO vs BNR Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, BNR has a market cap of 17.4M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while BNR trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas BNR's P/E ratio is -18.97. In terms of profitability, PRPO's ROE is -0.08%, compared to BNR's ROE of -0.13%. Regarding short-term risk, PRPO is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
PRPO vs CEMI Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas CEMI's P/E ratio is -0.63. In terms of profitability, PRPO's ROE is -0.08%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, PRPO is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
PRPO vs ENZ Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas ENZ's P/E ratio is -2.24. In terms of profitability, PRPO's ROE is -0.08%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, PRPO is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
PRPO vs PMD Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas PMD's P/E ratio is -5.24. In terms of profitability, PRPO's ROE is -0.08%, compared to PMD's ROE of -0.32%. Regarding short-term risk, PRPO is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
PRPO vs ME Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas ME's P/E ratio is -0.03. In terms of profitability, PRPO's ROE is -0.08%, compared to ME's ROE of -3.47%. Regarding short-term risk, PRPO is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
PRPO vs MYNZ Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, PRPO's ROE is -0.08%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, PRPO is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check MYNZ's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
PRPO vs BIAFW Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, BIAFW has a market cap of 12.1M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while BIAFW trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas BIAFW's P/E ratio is 1.29. In terms of profitability, PRPO's ROE is -0.08%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, PRPO is more volatile compared to BIAFW. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check BIAFW's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
PRPO vs CHEK Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas CHEK's P/E ratio is -0.43. In terms of profitability, PRPO's ROE is -0.08%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, PRPO is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
PRPO vs CNTG Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas CNTG's P/E ratio is -0.23. In terms of profitability, PRPO's ROE is -0.08%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, PRPO is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
PRPO vs ADVB Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, ADVB has a market cap of 8.8M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while ADVB trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas ADVB's P/E ratio is -58.00. In terms of profitability, PRPO's ROE is -0.08%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, PRPO is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
PRPO vs NDRA Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while NDRA trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas NDRA's P/E ratio is -0.90. In terms of profitability, PRPO's ROE is -0.08%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, PRPO is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
PRPO vs APDN Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas APDN's P/E ratio is -0.10. In terms of profitability, PRPO's ROE is -0.08%, compared to APDN's ROE of -7.23%. Regarding short-term risk, PRPO is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
PRPO vs NVTA Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas NVTA's P/E ratio is -0.00. In terms of profitability, PRPO's ROE is -0.08%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, PRPO is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
PRPO vs LMDXW Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, PRPO's ROE is -0.08%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, PRPO is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
PRPO vs LMDX Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas LMDX's P/E ratio is -0.01. In terms of profitability, PRPO's ROE is -0.08%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, PRPO is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
PRPO vs DMTK Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas DMTK's P/E ratio is -0.04. In terms of profitability, PRPO's ROE is -0.08%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, PRPO is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
PRPO vs NOTV Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas NOTV's P/E ratio is -0.03. In terms of profitability, PRPO's ROE is -0.08%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, PRPO is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check NOTV's competition here
iSpecimen Inc. (NASDAQ: ISPC)
PRPO vs ISPC Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, ISPC has a market cap of 2.7M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while ISPC trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas ISPC's P/E ratio is -0.03. In terms of profitability, PRPO's ROE is -0.08%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, PRPO is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check ISPC's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
PRPO vs BIAF Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, BIAF has a market cap of 2.5M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while BIAF trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas BIAF's P/E ratio is -0.71. In terms of profitability, PRPO's ROE is -0.08%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, PRPO is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
PRPO vs SQL Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas SQL's P/E ratio is -0.40. In terms of profitability, PRPO's ROE is -0.08%, compared to SQL's ROE of -30.46%. Regarding short-term risk, PRPO is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
PRPO vs AWH Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas AWH's P/E ratio is -0.09. In terms of profitability, PRPO's ROE is -0.08%, compared to AWH's ROE of +1.62%. Regarding short-term risk, PRPO is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
PRPO vs HTGM Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas HTGM's P/E ratio is -0.03. In terms of profitability, PRPO's ROE is -0.08%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, PRPO is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
PRPO vs BIOC Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas BIOC's P/E ratio is -0.01. In terms of profitability, PRPO's ROE is -0.08%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, PRPO is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
PRPO vs SQLLW Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, PRPO's ROE is -0.08%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, PRPO is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
PRPO vs WGSWW Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, PRPO's ROE is -0.08%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, PRPO is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check WGSWW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
PRPO vs NDRAW Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas NDRAW's P/E ratio is N/A. In terms of profitability, PRPO's ROE is -0.08%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, PRPO is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check NDRAW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
PRPO vs MEUSW Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas MEUSW's P/E ratio is N/A. In terms of profitability, PRPO's ROE is -0.08%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, PRPO is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check MEUSW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
PRPO vs OCDX Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas OCDX's P/E ratio is -42.28. In terms of profitability, PRPO's ROE is -0.08%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, PRPO is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check OCDX's competition here
Danaher Corporation (NYSE: DHR-PA)
PRPO vs DHR-PA Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, PRPO's ROE is -0.08%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, PRPO is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check DHR-PA's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
PRPO vs PRXL Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas PRXL's P/E ratio is 42.97. In terms of profitability, PRPO's ROE is -0.08%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, PRPO is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for PRPO.Check PRXL's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
PRPO vs BNGOW Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas BNGOW's P/E ratio is N/A. In terms of profitability, PRPO's ROE is -0.08%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, PRPO is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
PRPO vs CHEKZ Comparison October 2026
Precipio, Inc. (NASDAQ: PRPO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPO stands at 41.8M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, PRPO is priced at $23.45 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPO currently has a P/E ratio of -36.08, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, PRPO's ROE is -0.08%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, PRPO is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for PRPO.Check CHEKZ's competition here